Nucleoside Analogues Exerting Antiviral Activity Through a Non-nucleoside Mechanism

Nucleosides, Nucleotides and Nucleic Acids

Volumn 23, Issue 1-2, 2004, Pages 457-470

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

HCMV; HIV; Neucloside analogues

Indexed keywords

1 [(2 HYDROXYETHOXY)METHYL] 6 (PHENYLTHIO)THYMINE; 1 [(2 HYDROXYETHOXY)METHYL] 6 (PHENYLTHIO)THYMINE DERIVATIVE; 2 (CYCLOHEXYLTHIO) 3,4 DIHYDRO 5 METHYL 6 (3 METHYLBENZYL) 4 OXOPYRIMIDINE; 3,4 DIHYDRO 6 BENZYL 3 OXOPYRIMIDINE; 5 ETHYL 1 BENZYLOXYMETHYL 6 (PHENYLTHIO)URACIL; 5 ETHYL 1 ETHOXYMETHYL 6 (3,5 DIMETHYLBENZYL)URACIL; 5 ISOPROPYL 1 ETHOXYMETHYL 6 BENZYLURACIL; 5 ISOPROPYL 2 [(METHYLTHIOMETHYL)THIO] 6 (BENZYL)PYRIMIDIN 4(1H) ONE; [(2',5' BIS O (TERT BUTYLDIMETHYLSILYL) BETA DEXTRO RIBOFURANOSYL] 3' SPIRO 5'' (4 AMINO 1'', 2'' OXATHIOLE 2'',2'' DIOXIDE)THYMINE] DERIVATIVE; ACICLOVIR; BENZIMIDAVIR; CF 1368; CF 1851; CF 2160; CF 2161; CIDOFOVIR; EMIVIRINE; FURO[2,3 D]PYRIMIDINE NUCLEOSIDE DERIVATIVE; GANCICLOVIR; MC 1047; MC 1220; NUCLEOSIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SANGIVAMYCIN; SANGIVAMYCIN DERIVATIVE; STAVUDINE; TOYOCAMYCIN; TOYOCAMYCIN DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG ACTIVITY; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HIV; HIV INFECTIONS; HUMANS; PYRIMIDINE NUCLEOSIDES;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 1642486744     PISSN: 15257770     EISSN: None     Source Type: Journal    
DOI: 10.1081/NCN-120028339     Document Type: Article

References (56)

1. De Clercq, E.; Balzarini, J.; Madej, D.; Hansske, F.; Robins, M.J. Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin. J. Med. Chem. 1987, 30, 481-486.
2. Gupta, P.K.; Daunert, S.; Nassiri, M.R.; Wotring, L.L.; Drach, J.C.; Townsend, L.B. Synthesis, cytotoxicity, and antiviral activity of some acyclic analogues of the pyrrolo[2,3-d]pyrimidine nucleoside antibiotics tubercidin, toyocamycin, and sangivamycin. J. Med. Chem. 1989, 32, 402-408.
3. Jacobson, J.G.; Renau, T.E.; Nassiri, M.R.; Sweier, D.G.; Breitenbach, J.M.; Townsend, L.B.; Drach, J.C. Nonnucleoside pyrrolopyrimidines with a unique mechanism of action against human cytomegalovirus. Antimicrob. Agents Chemother. 1999, 43, 1888-1894.
4. Underwood, M.R.; Harvey, R.J.; Stanat, S.C.; Hemphill, M.L.; Miller, T.; Drach, J.C.; Townsend, L.B.; Biron, K.K. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. J. Virol. 1998, 72, 717-725.
5. Krosky, P.M.; Underwood, M.R.; Turk, S.R.; Feng, K.W.; Jain, R.K.; Ptak, R.G.; Westerman, A.C.; Biron, K.K.; Townsend, L.B.; Drach, J.C. Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. J. Virol. 1998, 72, 4721-4728.
6. Biron, K.K.; Harvey, R.J.; Chamberlain, S.C.; Good, S.S.; Smith, A.A., III; Davis, M.G.; Talarico, C.L.; Miller, W.H.; Ferris, R.; Dornsife, R.E.; Stanat, S.C.; Drach, J.C.; Townsend, L.B.; Koszalka, G.W. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother. 2002, 46, 2365-2372.
7. Krosky, P.M.; Baek, M.C.; Coen, D.M. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J. Virol. 2003, 77, 905-914.
8. Koszalka, G.W.; Johnson, N.W.; Good, S.S.; Boyd, L.; Chamberlain, S.C.; Townsend, L.B.; Drach, J.C.; Biron, K.K. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob. Agents Chemother. 2002, 46, 2373-2380.
9. Lalezari, J.P.; Aberg, J.A.; Wang, L.H.; Wire, M.B.; Miner, R.; Snowden, W.; Talarico, C.L.; Shaw, S.; Jacobson, M.A.; Drew, W.L. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob. Agents Chemother. 2002, 46, 2969-2976.
10. De Clercq, E. New inhibitors of human cytomegalovirus (HCMV) on the horizon. J. Antimicrob. Chemother. 2003, 51, 1079-1083.
11. Kelley, J.L.; Kelsey, J.E.; Hall, W.R.; Krochmal, M.P.; Schaeffer, H.J. Pyrimidine acyclic nucleosides. 1-[(2-Hydroxyethoxy)methyl]pyrimidines as candidate antivirals. J. Med. Chem. 1981, 24, 753-756.
12. Kelley, J.L.; Krochmal, M.P.; Schaeffer, H.J. Pyrimidine acyclic nucleosides. 5-Substituted 1-[(2-aminoethoxy)methyl]uracils as candidate antivirals. J. Med. Chem. 1981, 24, 472-474.
13. Miyasaka, T.; Tanaka, H.; Baba, M.; Hayakawa, H.; Walker, R.T.; Balzarini, J.; De Clercq, E. A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)-methyl]-6-(phenylthio)thymine. J. Med. Chem. 1989, 32, 2507-2509.
14. Baba, M.; Tanaka, H.; De Clercq, E.; Pauwels, R.; Balzarini, J.; Schols, D.; Nakashima, H.; Perno, C.-F.; Walker, R.T.; Miyasaka, T. Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem. Biophys. Res. Commun. 1989, 165, 1375-1381.
15. Baba, M.; De Clercq, E.; Tanaka, H.; Ubasawa, M.; Takashima, H.; Sekiya, K.; Nitta, I.; Umezu, K.; Nakashima, H.; Mori, S.; Shigeta, S.; Walker, R.T.; Miyasaka, T. Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. U. S. A. 1991, 88, 2356-2360.
16. Baba, M.; De Clercq, E.; Tanaka, H.; Ubasawa, M.; Takashima, H.; Sekiya, K.; Nitta, I.; Umezu, K.; Walker, R.T.; Mori, S.; Ito, M.; Shigeta, S.; Miyasaka, T. Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives. Mol. Pharmacol. 1991, 39, 805-810.
17. Baba, M.; Shigeta, S.; Yuasa, S.; Takashima, H.; Sekiya, K.; Ubasawa, M. ; Tanaka, H.; Miyasaka, T.; Walker, R.T.; De Clercq, E. Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrob. Agents Chemother. 1994, 38, 688-692.
18. Szczech, G.M.; Furman, P.; Painter, G.R.; Barry, D.W.; Borroto-Esoda, K. ; Grizzle, T.B.; Blum, M.R.; Sommadossi, J.-P.; Endoh, R.; Niwa, T.; Yamamoto, M.; Moxham, C. Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2000, 44, 123-130.
19. Hopkins, A.L.; Ren, J.; Esnouf, R.M.; Willcox, B.E.; Jones, E.Y.; Ross, C.; Miyasaka, T.; Walker, R.T.; Tanaka, H.; Stammers, D.K.; Stuart, D.I. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J. Med. Chem. 1996, 39, 1589-1600.
20. Hopkins, A.L.; Ren, J.; Tanaka, H.; Baba, M.; Okamoto, M.; Stuart, D.I.; Stammers, D.K. Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants. J. Med. Chem. 1999, 42, 4500-4505.
21. Danel, K.; Pedersen, E.B.; Nielsen, C. Synthesis and anti-HIV-1 activity of novel 2, 3-dihydro-7H-thiazolo[3,2-a]pyrimidin-7-ones. J. Med. Chem. 1998, 41, 191-198.
22. Tanaka, H.; Walker, R.T.; Hopkins, A.L.; Ren, J.; Jones, E.Y.; Fujimoto, K.; Hayashi, M.; Miyasaka, T.; Baba, M.; Stammers, D.K.; Stuart, D.I. Allosteric inhibitors against HIV-1 reverse transcriptase: design and synthesis of MKC-442 analogues having an ω-functionalized acyclic structure. Antivir. Chem. Chemother. 1998, 9, 325-332.
23. El-Brollosy, N.R.; Jorgensen, P.T.; Dahan, B.; Boel, A.M.; Pedersen, E.B.; Nielsen, C. Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants. J. Med. Chem. 2002, 45, 5721-5726.
24. Mai, A.; Artico, M.; Sbardella, G.; Quartarone, S.; Massa, S.; Loi, A.G. ; De Montis, A.; Scintu, F.; Putzolu, M.; La Colla, P. Dihydro(alkylthio) (naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series. J. Med. Chem. 1997, 40, 1447-1454.
25. Mai, A.; Artico, M.; Sbardella, G.; Massa, S.; Novellino, E.; Greco, G.; Loi, A.G.; Tramontano, E.; Marongiu, M.E.; La Colla, P. 5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3,4-dihydropyrimidin-4(3H) -ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives. J. Med. Chem. 1999, 42, 619-627.
26. Mai, A.; Sbardella, G.; Artico, M.; Ragno, R.; Massa, S.; Novellino, E.; Greco, G.; Lavecchia, A.; Musiu, C.; La Colla, M.; Murgioni, C.; La Colla, P.; Loddo, R. Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H) -ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase. J. Med. Chem. 2001, 44, 2544-2554.
27. Sudbeck, E.A.; Mao, C.; Vig, R.; Venkatachalam, T.K.; Tuel-Ahlgren, L.; Uckun, F.M. Structure-based design of novel dihydroalkoxybenzyloxopyrimidine derivatives as potent nonnucleoside inhibitors of the human immunodeficiency virus reverse transcriptase. Antimicrob. Agents Chemother. 1998, 42, 3225-3233.
28. Costi, R.; Di Santo, R.; Artico, M.; Massa, S.; Lavecchia, A.; Marceddu, T.; Sanna, L.; La Colla, P.; Marongiu, M.E. Structure-activity relationship studies on potential non-nucleoside DABO-like inhibitors of HIV-1 reverse transcriptase. Antivir. Chem. Chemother. 2000, 11, 117-133.
29. Sbardella, G.; Mai, A.; Artico, M.; Chimenti, P.; Massa, S.; Loddo, R.; Marongiu, M.E.; La Colla, P.; Pani, A. Structure-activity relationship studies on new DABOs: effect of substitutions at pyrimidine C-5 and C-6 positions on anti-HIV-1 activity. Antivir. Chem. Chemother. 2001, 12, 37-50.
30. Pani, A.; Musiu, C.; Loi, A.G.; Mai, A.; Loddo, R.; La Colla, P.; Marongiu, M.E. DABOs as candidates to prevent mucosal HIV transmission. Antivir. Chem. Chemother. 2001, 12 (Suppl. 1), 51-59.
31. Balzarini, J.; Pérez-Pérez, M.-J.; San-Félix, A.; Schols, D.; Perno, C.F.; Vandamme, A.-M.; Camarasa, M.-J.; De Clercq, E. 2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″ -(4″-amino-1″,2″-oxathiole-2″,2′-dioxide) pyrimidine (TSAO) nucleoside analogues: highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proc. Natl. Acad. Sci. U. S. A. 1992, 89, 4392-4396.
32. Camarasa, M.-J.; Pérez-Pérez, M.-J.; San-Félix, A.; Balzarini, J.; De Clercq, E. 3′-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2′-5′-bis-O-(tert-butyldimethylsilyl)-β -D-xylo- and -ribofuranose]-3′-spiro-5″-[4″-amino-1″ ,2″-oxathiole 2″,2″-dioxide] (TSAO) pyrimidine nucleosides. J. Med. Chem. 1992, 35, 2721-2727.
33. Balzarini, J.; Pérez-Pérez, M.-J.; San-Félix, A.; Camarasa, M.-J.; Bathurst, I.C.; Barr, P.J.; De Clercq, E. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2′,5′ -bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]-3′-spiro-5″ -(4″-amino-1″,2″-oxathiole-2″,2″-dioxide)thymine (TSAO-T). J. Biol. Chem. 1992, 267, 11831-11838.
34. Pérez-Pérez, M.-J.; San-Félix, A.; Balzarini, J.; De Clercq, E.; Camarasa, M.-J. TSAO analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2′,5′ -bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]-3′-spiro-5″ -(4″-amino-1″,2″-oxathiole-2″,2″-dioxide) pyrimidine and pyrimidine-modified nucleosides. J. Med. Chem. 1992, 35, 2988-2995.
35. Velázquez, S.; San-Félix, A.; Pérez-Pérez, M.-J.; Balzarini, J.; De Clercq, E.; Camarasa, M.-J. TSAO analogues. 3. Synthesis and anti-HIV-1 activity of 2′,5′ -bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl 3′-spiro-5″ -(4″-amino-1″,2″-oxathiole 2″,2″-dioxide) purine and purine-modified nucleosides. J. Med. Chem. 1993, 36, 3230-3239.
36. Balzarini, J.; Velázquez, S.; San-Félix, A.; Karlsson, A.; Pérez-Pérez, M.-J.; Camarasa, M.-J.; De Clercq, E. Human immunodeficiency virus type 1-specific [2′,5′ -bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]-3′-spiro-5″ -(4″-amino-1″,2″-oxathiole-2″,2″-dioxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1-specific non-nucleoside analogues. Mol. Pharmacol. 1993, 43, 109-114.
37. Balzarini, J.; Karlsson, A.; Pérez-Pérez, M.-J.; Vrang, L. ; Walbers, J.; Zhang, H.; Öberg, B.; Vandamme, A.-M.; Camarasa, M.-J.; De Clercq, E. HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amno acid substitutions in the reverse transcriptase. Virology 1993, 192, 246-253.
38. 138 → Lys on the p51 subunit. J. Biol. Chem. 1994, 269, 25255-25258.
39. Balzarini, J.; Karlsson, A.; Vandamme, A.-M.; Pérez-Pérez, M.-J.; Zhang, H.; Vrang, L.; Öberg, B.; Bäckbro, K.; Unge, T.; San-Félix, A.; Velázquez, S.; Camarasa, M.-J.; De Clercq, E. Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2′,5′ -bis-O-(tert-butyldimethylsilyl)-3′-spiro-5′-(4′ -amino-1″,2″-oxathiole-2″,2″-dioxide)] -β-D-pentofuranosyl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors. Proc. Natl. Acad. Sci. U. S. A. 1993, 90, 6952-6956.
40. San-Félix, A.; Velázquez, S.; Pérez-Pérez, M.-J.; Balzarini, J.; De Clercq, E.; Camarasa, M.-J. Novel series of TSAO-T derivatives. Synthesis and anti-HIV-1 activity of 4-, 5-, and 6-substituted pyrimidine analogues. J. Med. Chem. 1994, 37, 453-460.
41. Alvarez, R.; Velázquez, S.; San-Félix, A.; Aquaro, S.; De Clercq, E.; Perno, C.-F.; Karlsson, A.; Balzarini, J.; Camarasa, M.-J. 1,2,3-Triazole-[2′,5′-bis-O-(tert-butyldimethylsilyl) -β-D-ribofuranosyl]-3′-spiro-5″-(4″-amino-1″, 2″-oxathiole 2″,2″-dioxide) (TSAO) analogues: synthesis and anti-HIV-1 activity. J. Med. Chem. 1994, 37, 4185-4194.
42. Ingate, S.; San-Félix, A.; De Clercq, E.; Balzarini, J.; Camarasa, M.-J. Synthesis of [1-[2′,5′-bis-O-(t-butyldimethylsilyl)-β -L-ribofuranosyl]thymine]-3′-spiro-5″-(4″-amino-1″, 2″-oxathiole-2″,2″-dioxide) (L-TSAO-T). Nucleosides Nucleotides 1995, 14, 299-301.
43. Ingate, S.; De Clercq, E.; Balzarini, J.; Camarasa, M.-J. Novel L-lyxo and 5′-deoxy-5′-modified TSAO-T analogs: synthesis and anti-HIV-1 activity. Antivir. Res. 1996, 32, 149-164.
44. Lobatón, E.; Velázquez, S.; San-Félix, A.; De Clercq, E.; Balzarini, J.; Camarasa, M.-J. 4″-H-TSAO-T, a novel prototype in the HIV-1-specific TSAO family. Nucleosides Nucleotides Nucleic Acids 2001, 20, 711-714.
45. Velázquez, S.; Chamorro, C.; Pérez-Pérez, M.-J.; Alvarez, R.; Jimeno, M.-L.; Martín-Domenech, A.; Pérez, C.; Gago, F.; De Clercq, E.; Balzarini, J.; San-Félix, A.; Camarasa, M.-J. Abasic analogues of TSAO-T as the first sugar derivatives that specifically inhibit HIV-1 reverse transcriptase. J. Med. Chem. 1998, 41, 4636-4647.
46. Chamorro, C.; Pérez-Pérez, M.-J.; Rodríguez-Barrios, F.; Gago, F.; De Clercq, E.; Balzarini, J.; San-Félix, A.; Camarasa, M.-J. Exploring the role of the 5′-position of TSAO-T. Synthesis and anti-HIV evaluation of novel TSAO-T derivatives. Antivir. Res. 2001, 50, 207-222.
47. Velázquez, S.; Alvarez, R.; San-Félix, A.; Jimeno, M.L.; De Clercq, E.; Balzarini, J.; Camarasa, M.-J. Synthesis and anti-HIV activity of [AZT]-[TSAO-T] and [AZT]-[HEPT] dimers as potential multifunctional inhibitors of HIV-1 reverse transcriptase. J. Med. Chem. 1995, 38, 1641-1649.
48. Velázquez, S.; Tunón, V.; Jimeno, M.L.; Chamorro, C.; De Clercq, E.; Balzarini, J.; Camarasa, M.-J. Potential multifunctional inhibitors of HIV-1 reverse transcriptase. Novel [AZT]-[TSAO-T] and [d4T]-[TSAO-T] heterodimers modified in the linker and in the dideoxynucleoside region. J. Med. Chem. 1999, 42, 5188-5196.
49. Lobatón, E.; Rodríguez-Barrios, F.; Gago, F.; Pérez-Pérez, M.-J.; De Clercq, E.; Balzarini, J.; Camarasa, M.-J. ; Velázquez, S. Synthesis of 3″-substituted TSAO derivatives with anti-HIV-1 and anti-HIV-2 activity through an efficient palladium-catalyzed cross-coupling approach. J. Med. Chem. 2002, 45, 3934-3945.
50. Rodriguez-Barrios, F.; Perez, C.; Lobaton, E.; Velázquez, S.; Chamorro, C.; San-Félix, A.; Pérez-Pérez, M.-J.; Camarasa, M.-J.; Pelemans, H.; Balzarini, J.; Gago, F. Identification of a putative binding site for [2′,5′-bis-O-(tert-butyldimethylsilyl)-β -D-ribofuranosyl]-3′-spiro-5″-(4″-amino-1″, 2″-oxathiole-2″,2″-dioxide)thymine (TSAO) derivatives at the p51-p55 interface of HIV-1 reverse transcriptase. J. Med. Chem. 2001, 44, 1853-1865.
51. McGuigan, C.; Yarnold, C.J.; Jones, G.; Velázquez, S.; Barucki, H.; Brancale, A.; Andrei, G.; Snoeck, R.; De Clercq, E.; Balzarini, J. Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base. J. Med. Chem. 1999, 42, 4479-4484.
52. McGuigan, C.; Barucki, H.; Carangio, A.; Blewett, S.; Andrei, G.; Snoeck, R.; De Clercq, E.; Balzarini, J.; Erichsen, J.T. Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain. J. Med. Chem. 2000, 43, 4993-4997.
53. De Clercq, E. Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo[2,3-d]pyrimidine nucleoside analogues. Med. Res. Rev. 2003, 23, 253-274.
54. Sienaert, R.; Naesens, L.; Brancale, A.; De Clercq, E.; McGuigan, C.; Balzarini, J. Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase. Mol. Pharmacol. 2002, 61, 249-254.
55. McGuigan, C.; Pathirana, R.N.; De Clercq, E.; Balzarini, J. Discovery of a new family of bicyclic dideoxy nucleosides which inhibit HCMV by a non-nucleoside mechanism. 16th International Conference on Antiviral Research, Savannah, Georgia, USA, 27 April-1 May 2003. Antivir. Res. 2003, 57, A57 No. 61.
56. Andrei, G.; Balzarini, J.; De Clercq, E.; Pathirana, R.; McGuigan, C.; Snoeck, R. In New Bicyclic Nucleoside Analogues (BCNAs) Show Selective and Specific Activity Against Human Cytomegalovirus (HCMV), 9th International Cytomegalovirus Workshop and First International Betaherpesvirus Workshop, Maastricht, The Netherlands, May 20-25, 2003; Final Programme and Abstract Book, abstract H.02, p. 71 (2003).